Tagrisso (osimertinib)

Numéro de dossier de l’AMC: 23274
État des négociations:
En négociation
Indication(s):
​For the treatment of patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations) and whose disease has not progressed during or following platinum-based chemoradiation therapy (CRT).
Promoteur/fabricant:
AstraZeneca Canada Inc.
Numéro de projet de l’AMC:
PC0398-000
Lettre d’entente de l’APP:
Conclusion du processus de négociation:
Sans objet